Oncoshot, a platform for health insights exchange, has partnered with Zhejiang Ablaze Medicine, a clinical trial solutions provider, to drive data-powered drug development in China.

The collaboration combines Oncoshot’s proficiency in data analysis and insights generation with Ablaze’s recent expansion into data management and clinical trials recruitment.

The partnership allows Oncoshot to venture into the rapidly growing healthcare market in China alongside a recognised domestic leader and facilitates geographic expansion in China/APAC by integrating Oncoshot’s data and analytics capabilities with Ablaze’s substantial regional trial operations.

With more than two decades of experience, Ablaze stands as a prominent expert in clinical trial management in China, boasting extensive access to biopharma and hospital networks. The clinical trial infrastructure enables Ablaze to seamlessly coordinate end-to-end processes necessary for flawless clinical trial execution.

Backed by over 20 years of trial expertise, Ablaze currently supports over 200 global customers across four continents, optimizing research outcomes. The collaboration with Oncoshot signifies the next phase of growth for Ablaze, fuelled by technology-powered innovation.

For Oncoshot’s biopharma clientele, the joint utilisation of technology-powered trial design, guided by data-informed patient recruitment and protocol optimisation, holds the promise of enhancing clinical research outcomes through advanced analytics.

The alliance will see the two companies working together to apply advanced analytics and new technological paradigms, elevating clinical trials to improve the speed, quality, efficiency, and patient-centricity of drug development programmes on a global scale.

Ablaze director and co-founder Marco Meng said: “Together, we can help predict optimal trial sites, enhance patient matching and retention, and enable a continuous cycle of trial design improvements powered by data and technology. We are excited about the immense potential to accelerate therapies for patients.”